It is appropriate to conclude this issue with a vignette of some problems and future prospects for diabetes in the last decade of the century. The reader will appreciate that coverage of the topic is selective, that the views expressed are the author' s own and that references for further read ing are kept to a minimum.
The first and most obvious problem is that the diabetic syndrome is common and prevalence is certainly increas ing. In the Northern Hemisphere, especially in Europe, the incidence of insulin-dependent (type 1) diabetes has risen inexorably over the past decade and much evidence (dis cordance in identical twins, disease clustering, migration studies and variations in incidence over short time periods) indicates the clear importance of environmental factors in disease pathogenesis. For non-insulin-depend ent (type 2) diabetes, it is unhappily evident that the disease is held in check only by the misery of famine in many underdeveloped countries, and even here the dietary consequences of malnutrition may induce carbohydrate intolerance.' For First World countries, zero population growth and an ageing population guarantee the rise of non-insulin-dependent diabetes and there is no reason to believe that the World Health Organization'S estimate of 3% world popUlation prevalence of diabetes is inaccurate: indeed it may be conservative.
A second grave problem is the inaccuracy with which the gross financial and social consequences of diabetes and its treatment, especially its complications, are recorded by modem health care systems. There is now excellent evidence that diabetes as a cause of hospital admission in the United Kingdom is seriously under estimated, perhaps by 100%, and accurate data are the pre requisite for proper funding and allocation of scarce resources (Fig. 1 ).2 Communities which have attempted formal measurement of the true costs of diabetes -the economics of a pregnancy, the rehabilitation of an ampu tee, provision for the blind, etc. -have been sobered by the enormity of sums involved but equally have accrued Eye (1993) 7,312-316 invaluable information as to which areas merit higher investment in preventive and therapeutic measures to miti gate the impact of the disease. 3 Thus a common disease is becoming more common and consumes increasing quantities of every society's health and welfare budgets. It is appropriate to consider briefly what prospects are envisaged to improve the situation and what preventive strategies may be employed.
PROSPECTS FOR DIABETES: PREVENTIVE STRATEGIES
Preventive strategies for diabetes in its broadest sense are three-layered (Table I) and will now be considered. Their classification in reverse order is not mere perversity; rather it reflects the increasing degree of difficulty in accom plishing worthy objectives as the focus moves through ter tiary to primary prevention.
Tertiary Preventive Strategies
Tertiary prevention can be considered as an exercise in damage limitation and comprises all measures which may be taken to limit the consequences of long-term diabetic complications (Table II) . In essence, it deals with a popu lation of patients who have suffered from overt diabetes for 5-15 years or more and are (or will become) disabled by microvascular disease. Major morbidity in such patients is caused by retinopathy, neuropathic foot ulcer ation with limb loss and end-stage renal failure. Prospects for improvement here rest almost entirely on more timely and wider use of established therapies. Detec tion and treatment of retinopathy at its optimal stage has been considered earlier in this issue and is of proven value in maintaining useful vision for the large majority of patients: two-thirds of those with maculopathy, more than 80% with proliferative retinal changes. For prevention and Diabetes-related admissions n=54
Newly diagnosed Diabetes n=22
Peripheral vascular surgery n=16
Eye surgery n=13 The under-reporting of hospital admissions of diabetic patients using a standard morbidity coding system (WHO lCD-9). treatment of foot ulceration, the process starts with proper patient education in foot care, extends through provision of a chiropody service which is readily accessible to all diabetics and concludes with the collaboration of a sur geon who has particular interest in diabetes and is expert in techniques for maintaining a vascular supply to the affected limb. Much experience has now accrued in the creation of integrated foot care service for diabetes. The benefits are so significant, without excessive allocation of new resources, that we may hope such services will steadily be developed in the regional diabetes centres. End-stage renal failure (ESRF) remains the most com plex and expensive to treat of the long-term problems, typically appearing after 15-25 years of insulin-depend ent diabetes but much earlier in non-insulin-dependent diabetes.4 Haemodialysis is the longest-established ther apy, but except in the United States (where two-thirds of all patients with ESRF receive this treatment) is not now regarded as the treatment of choice. Its limitations include premature death from macrovessel disease or sepsis and an exceedingly poor quality of life for many patients. It is also extremely expensive. In almost all other countries, including the United Kingdom, continuous ambulatory peritoneal dialysis (CAPO) is the treatment of choice for virtually all patients except those with severe physical dis ability or visual handicap. Physical and psychological quality of life is better than for haemodialysis, intermittent heparinisation is avoided, control of hypertension and gly caemia is improved and sepsis from the intraperitoneal catheter is the only serious complication. Above all the CAPO system is effective, simple and cheap enough to be sensibly contemplated by countries with under-developed health care systems. By contrast, the treatment of ESRF by living-donor or cadaveric graft is undoubtedly the best of all therapies and, since the introduction of cyclosporin as an immunosuppressant, yields results (in graft survival) comparable to those in non-diabetics. By reasons of cost, technology and organ availability alone, transplantation is likely to remain the province of affluent countries until well into the next century.
In summary, current strategies for tertiary prevention in diabetes are remarkably satisfactory and, save for kidney transplant, not prohibitively expensive for most national health services. Our real problem is to ensure that simple measures are properly used, and we need only look at the statistics for diabetic blindness to realise that there is much scope for improvement in contemporary clinical performance.
Secondary Preventive Strategies
Secondary preventive strategies (Table III) are deployed to control the metabolic abnormalities which ensue from chronic hyperglycaemia and its treatment. In the short term, such measures are used to prevent death from uncon trolled diabetes (due to ketoacidosis and other syndromes of metabolic decompensation) or neurological damage from inadvertent over-treatment (insulin-induced hypo glycaemia). The successful treatment of metabolic decompensation rests essentially upon early recognition of the condition and prompt treatment by careful adminis tration of appropriate insulin, fluid and electrolyte replace ment in these seriously ill patients. The principles of treating metabolic decompensation are very well estab lished in modem practice and should pose no special prob lems for the trained clinician. No patients now should die from failure to correct the acidosis or potassium deficit of a common medical emergency, but the continuing mor tality from ketoacidosis is a sad reminder that not all doc tors are equally skilled in its management. By contrast, occasional hypoglycaemic reactions are an unavoidable fact of life for virtually all insulin-treated patients but have excited particular concern in the past 5 years, stemming from speculation that modem human insulin formulations may diminish hypoglycaemic awareness and thereby increase the risk of severe, damaging hypoglycaemia. National diabetes organisations in the United Kingdom, United States and other countries have examined this proposition seriously and with great care: the weight of expert scientific opinion has concluded that human insulin therapy carries no special risks of facilitating hypogly-
ut controversy rumbles on and (having attracted the attention of the lay press) engenders considerable anxiety for many patients. Their understand able fears can be allayed first by reassurance that the older animal insulins (bovine and porcine) are still available for clinical use, and second by knowledge that a new gener ation of insulins is steadily being developed. Modem tech niques of recombinant DNA technology permit the insertion into host cells of synthetic genes which yield analogues of human insulin, usually by manipulation of the peptide sequence of its beta chain. Such 'designer mol ecules' can ensure the production of insulin formulations which will have different and more predictable action times when injected subcutaneously. The first new analo gues of human insulin are already appearing for clinical trial and carry the promise of finally removing the real or imagined hazards of recombinant human insulin.
Over a longer time course, secondary prevention in diabetes is focused upon measures which may prevent or limit the complications of the disease. A convincing body of evidence now indicates that diabetic microvascular disease can be contained or minimised if ambient gly caemic levels are consistently maintained at near normal values: in practical terms, this translates to blood glucose levels below 10 mmolll at all times. Small wonder, then, that much of the effort in modem diabetes care is directed to the goal of attaining 'good diabetic control' by careful A. C. MACCUISH patient education, frequently reinforced, widespread use of home blood glucose self-monitoring and use of gly cated protein assays (such as HbAl) to judge glycaemia. The difficulties of achieving and maintaining good control over months and years are always formidable and are insuperable for many patients, but potential benefits are so high as to justify the commitment involved. Success or failure can be judged by regular review, usually at annual intervals, to search specifically for the presence or absence of evolving complications and detection of other factors, especially hypertension, which may accelerate their appearance.
Of course it is accepted that full correction of all the metabolic abnormalities of the diabetic state is impossible without recourse to an artificial beta cell or restoration of endogenous insulin production. The first approach (use of a Biostator or similar device) is unrealistic and impossible for almost all patients, but the latter aim -implantation of a new beta cell colony -is slowly becoming more feasible. Earlier, heroic attempts by segmental grafts of cadaver pancreas have now been superseded by the much more promising technique of transplanting small nests of cul tured islet cells into the portal system. Such studies are in their infancy but islet cell transplantation has already been used successfully to treat and 'cure' a handful of adult patients with insulin-dependent diabetes and is likely to be used increasingly over the next decade.
Secondary preventive strategies must also envisage pharmacological intervention to limit or prevent the onset of microvacular disease. No single drug has yet been pro ven of conclusive value in this context, but at least on sound theoretical grounds it is possible that the aldose reductase inhibitors may limit the process of protein gly cation in many organs and that (for example) angiotensin converting enzyme (ACE) inhibitors or aminoguanidine may check the progression of diabetic nephropathy. All such therapies are currently the subject of formal clinical trials and it is to be hoped that one or more may find a use ful place in long-term diabetes management.
Finally, it is appropriate to conclude this section with the rather discouraging observation that at present we seem to have no means of containing the non-specific vas cular diseases (macrovessel disease) which are the leading causes of excess mortality in diabetes. In contrast to speci fic microvessel disease, epidemiological evidence and population screening indicates that very modest elevations of blood glucose, well short of frank diabetes, confer a major increase in risk of morbidity and mortality from myocardial infarction, stroke and peripheral vascular disease. Even the best -controlled of diabetic patients is unlikely to attain true normoglycaemia by any means over prolonged periods and it follows that at present we can do virtually nothing to reduce excess macrovessel disease in the diabetic popUlation.
Primary Preventive Strategies
The primary preventive strategies for diabetes are sum marised simply as any means used to reduce the incidence of the disease. It will at once be apparent that such measures are characterised equally by extreme difficulty and high promise.
Prospects for prevention of insulin-dependent diabetes are significant and hopeful (Table IV) . Much understand ing of the natural history of the disease has been acquired over the past 17 years or so. We are now near the stage where the genes involved in susceptibility to insulin dependent diabetes will be identified and sequenced, and before the end of the decade it will be possible to contem plate prevention of the condition by large-scale population screening of susceptible juveniles, using micromethods to screen for immunological or genetic markers in blood samples obtained by fingerprick estimation. Such a pro gramme would be reasonable only if we could be con fident of identifying the 1-3% of the population who are most susceptible to the disease, but small-scale screening studies of insulin-dependent diabetes in families do give real grounds for optimism.
A health care system committed to population screen ing must be matched by the prospect that safe and effective preventive therapies are possible. This is a very large caveat, and for insulin-dependent diabetes the prospects divide evenly into measures which shield susceptible per sons from the environmental triggers of an autoimmune disease and therapies which check established beta cell damage. As noted earlier, environmental factors are prob ably of major importance in initiating the majority of cases of insulin-dependent diabetes and broadly comprise com mon childhood viral infections (coxsackie, mumps, rubella, etc.) or ingested dietary allergens of which the most fascinating and perhaps most common is the bovine albumin peptide found in trace quantities in cow's milk. 6 Thus one approach to prevention envisages susceptible infants, identified shortly after birth, receiving a poly valent antiviral vaccine and breast rather than bottle feed ing to avoid exposure to autoimmune triggers.
For persons in whom the process of beta cell destruction has already started, up to and including the threshold of clinical diabetes, immunotherapy offers the only sensible prospect of cure. The chosen agent must perform in a diffi cult environment, where perhaps 85% of beta cell mass is already lost, and must be both effective and safe. No current drug meets these criteria: cyclosporin A has been used in this context and 'rescues' perhaps 20% of young persons who are given the drug at the very onset of overt diabetes. Its effects on the immune system are too non specific and in prolonged use it is too toxic, especially to the kidney, to be seriously considered as a routine treat ment. Better success depends upon progress in molecular biology, and therapeutic clonotypic vaccines already being developed to treat patients with cancer have enor mous potential applications for diabetes and other auto immune diseases.? Of equal current interest is the possible role of nicotinamide in prevention progression to insulin dependent diabetes in susceptible subjects with early evidence of beta cell damage. Nicotinamide is a water soluble group B vitamin which is effective in preventing onset of diabetes in animal models by manifold actions including free radical scavenging to reduce DNA damage, restoration of islet cell content of NAD towards normal and suppression of MHC class II antigen on islet cells. In man, the drug has been effective in preventing diabetes in persons with high levels of islet cell antibodies (ICA) and prolonging beta cell function in recently diagll(�sed insulin-dependent diabetes. Most seductively, it appears to be free of any serious side effects and will shortly be the centrepoint of an ambitious, international randomised pla cebo-controlled intervention study (END IT, the European Nicotinamide Diabetes Intervention Trial). In short, pros pects for primary prevention of insulin-dependent diabetes are indeed exciting.
By contrast, current prospects for primary prevention of non-insulin-dependent diabetes are only the first faltering steps down a very long road (Table V) . The control of simple obesity, so often the precipitating factor of the disease in middle age, still eludes us despite all manner of dietary, psychological and pharmacological intervention and all the social pressures which have generated the slim ming industry of affluent societies. But it can be said with certainty that in the 1990s we have at least recognised that approximately 60 distinct genetic disorders are associated with clinical diabetes, and although many are rare it is apparent that gene mutations at many different loci can affect glucose metabolism.8 The process of penetrating this genetic maze has now started with the recent demon stration that one well-characterised form of non-insulin dependent, maturity-onset diabetes of the young (MODY) is linked to a nonsense mutation of the gene on chro mosome 7p which codes for glucokinase.9 Beyond a doubt, the genetic basis of multiple other syndromes of non-insulin-dependent diabetes will steadily be disclosed by the march of molecular biology. An understanding of the genesis of these disorders carries also the tantalising prospect -still decades distant, hedged by ethical prob lems -of gene therapy by regulation, switching or manipulation. 
CONCLUSIONS
Clinical diabetes mellitus is the commonest endocrine disease in the world and embraces a large group of dis orders. The incidence of insulin-dependent and non insulin-dependent diabetes will continue to rise steadily for the rest of this century and beyond. The severe mor bidity, economic and social consequences of diabetes will be identified with increasing accuracy. Tertiary preventive strategies for diabetes will improve slowly if currently available treatments are properly deployed. Strategies for secondary prevention will improve steadily, assisted by advances in recombinant DNA technology, clinical phar macology and therapeutics. The primary prevention of insulin-dependent diabetes is about to emerge as a feasible prospect and promises incalculable benefits. The genetic basis for many of the disorders which induce non-insulin dependent diabetes will be established before the end of the decade, but in the foreseeable future there are no real prospects of accomplishing a cure.
